See Bubela T., Guebert J., Mishra A (2015) "Use and Misuse of Material Transfer Agreements: Lessons in Proportionality from Research Repositories, and Litigation," PLoS Biol 13(2), p. 7.

A Material Transfer Agreement (MTA) is a contract between a provider of a material and the recipient that memorializes the rights and responsibilities regarding research material. It defines who owns ...

A Material Transfer Agreement (MTA) governs the transfer of biological, chemical, archeological and other materials from one organization to another. Usually the materials in question are proprietary ...

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc. ( ...

Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement ("MTA") with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH TM ...

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus. Business Wire . Wed, Oct 2, 2024, 8:00 AM 6 min read. In This Article: IPA .

Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement ("MTA") with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH TM ...

Under this agreement, Biotheus will receive a specialized antibody asset from Talem Therapeutics, a subsidiary of ImmunoPrecise Antibodies. Biotheus plans to use this asset in conjunction with its ...

Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement with a pharmaceutical company to evaluate Lexaria's DehydraTECH TM technology in a ...

VICTORIA, British Columbia & ZHUHAI, China, October 02, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and ...

Detailed price information for Immunoprecise Antibodies Ltd (IPA-Q) from The Globe and Mail including charting and trades.